novo nordisk semaglutide clinical trials announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity A new round of data

Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C, Reddy KR, Chiang CW, Mumtaz K

While this may be related to individual patient factors, it still raises safety concerns that need further confirmation

The challenge is that GLP-1s for type 2 diabetes are often prescribed as a last resort, only after other treatments have failed or complications have developed

[37,38] Unlike GIP, this peptide could maintain its effects in patients with T2D and was quickly recognized as having remarkable antidiabetic effects in clinical studies

It does have a subtle chemical-like taste thats hard to ignore, according to Walker